NCT06735742

A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

TALZENNA Capsules Special Investigation - Investigation on BRCA Mutation-Positive and HER2-Negative Unresectable or Recurrent Breast Cancer With a History of Cancer Chemotherapy -

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 3 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 0 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn about the safety of TALZENNA for the patients with breast cancer that cannot be removed by surgery and has come back. These participants also have a past treatment with medicines that try to stop the growth of cancer cells. This study is seeking for participants who: * have breast cancer that cannot be removed by surgery and has come back * have not used this medicine before. All patients in this study will receive TALZENNA according to the prescriptions. Patients will be followed up to 52 weeks (12 months) from the day of start of treatment start (Day 1). However, in cases where treatment has been completed or stopped less than 52 weeks (12 months) after the start of giving study medicine, the participants will be checked until completion (discontinuation) of treatment.

Conditions

• Breast Cancer

Timeline

• Start date: 2025-04-12
• Primary completion: 2029-03-30
• Completion: 2029-03-30
• First posted: 2024-12-16
• Last updated: 2025-11-17

Locations

1 site across 1 country: Japan